Thursday, October 26, 2023
ERS Genomics Limited ('ERS') is pleased to announce a novel licensing agreement with the CHUM Research Centre ('CRCHUM'). This non-exclusive agreement grants CRCHUM research rights to ERS's CRISPR/Cas9 patent portfolio.
ERS Genomics, was awarded the Nobel Prize in 2020 for her discovery of CRISPR/Cas9. Consequently, ERS's patent portfolio represents the definitive collection of proprietary rights related to this gene editing technology.
CRCHUM, affiliated with the University of Montreal, stands as the largest research center in the field of biomedical sciences and healthcare in Canada, known for its size and modern facilities.
Vincent Poitout, Director of Research at the Centre hospitalier de l'Université de Montréal (CHUM) and Scientific Director of CRCHUM, emphasized the importance of this new license. He stated, "With the acquisition of this license, the CHUM Research Centre now has both the technological capabilities and the legal authorization to engage in research collaborations with commercial partners."
ERS Genomics, expressed his enthusiasm for the agreement and noted the growing prominence of Canada in the global biotechnology sector. He emphasized that this licensing agreement with CRCHUM is a significant step toward expanding the global use of CRISPR/Cas9, particularly in Montreal's thriving bio-economy.
The financial terms of the agreement remain confidential.
The CHUM Research Centre (CRCHUM) is one of North America's leading hospital research centers. It is committed to improving the health of adults through a range of research disciplines, including basic science, clinical research, and population health. CRCHUM boasts a team of over 2,150 individuals, including approximately 500 researchers and nearly 650 students and postdoctoral fellows actively contributing to research endeavors.